Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Presentation TCT 2024

REC/CAGE FREE

Presenter: Donald Cutlip

October 30, 2024

Presentation TCT 2023

SELUTION DCB

Presenter: Donald Cutlip

October 25, 2023

Presentation TCT 2023

Status Quo on SELUTION4ISR & SELUTION4DeNovo

Presenter: Donald Cutlip

October 24, 2023

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

Presentation TCT 2022

When Do I Use Mechanical Support for Left Main PCI?

Presenter: Donald Cutlip

September 18, 2022

News Features

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Michael O'Riordan

December 02, 2020

News Daily News

Making Sense of MI: EXCEL and SYNTAX Tackle Event Definitions

Michael O'Riordan

September 28, 2020

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

Presentation TCT 2018

The Methods for Coronary Stent Development

Presenter: Mitchell W. Krucoff, Gregg W. Stone, Donald Cutlip

September 21, 2018

Presentation TCT 2017

Emerging Thromboresistant BMS 1: Cobra PzF Stents

Presenter: Julinda Mehilli, Giulio G. Stefanini, Donald Cutlip

October 30, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

Presentation TCT 2016

LEADERS FREE: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Donald Cutlip

October 31, 2016

Presentation TCT 2016

The Newest Durable Polymer-Based DES: BioNir and Outcomes From Nireus Phase II and Bionics Pivotal Trials

Presenter: Donald Cutlip, Christian Hengstenberg, David E. Kandzari

October 31, 2016

Presentation TCT 2016

Can Passive Coatings Make a Difference: Results With the COBRA PzF Nanocoated Coronary Stent

Presenter: Donald Cutlip, Christian Hengstenberg, Sigmund Silber

October 31, 2016

Presentation TCT 2016

Evolution of Durable PolymerBased DES: Clinical Perspectives on Design, Safety, and Efficacy

Presenter: Donald Cutlip, Christian Hengstenberg, David G. Rizik

October 31, 2016

Presentation TCT 2016

Evolution of Durable PolymerBased DES: Pathologic Perspectives on Design, Safety, and Efficacy

Presenter: Donald Cutlip, Christian Hengstenberg, Michael Joner

October 31, 2016

News Daily News

Timing and Type of Events Post-PCI Have Implications for Prognosis—and Honest Discussions With Patients

Yael L. Maxwell

July 05, 2016

News Daily News

Sluggish CMS Reimbursement Lags Cardiac Device Approvals: Should Value Endpoints be Added to Trials?

Yael L. Maxwell

May 02, 2016

Advertisement

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

REC/CAGE FREE

SELUTION DCB

Status Quo on SELUTION4ISR & SELUTION4DeNovo

New Biomarker-Based Risk Score Performs Well in ACS

When Do I Use Mechanical Support for Left Main PCI?

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Making Sense of MI: EXCEL and SYNTAX Tackle Event Definitions

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

The Methods for Coronary Stent Development

Emerging Thromboresistant BMS 1: Cobra PzF Stents

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

LEADERS FREE: Pros and Cons

The Newest Durable Polymer-Based DES: BioNir and Outcomes From Nireus Phase II and Bionics Pivotal Trials

Can Passive Coatings Make a Difference: Results With the COBRA PzF Nanocoated Coronary Stent

Evolution of Durable PolymerBased DES: Clinical Perspectives on Design, Safety, and Efficacy

Evolution of Durable PolymerBased DES: Pathologic Perspectives on Design, Safety, and Efficacy

Timing and Type of Events Post-PCI Have Implications for Prognosis—and Honest Discussions With Patients

Sluggish CMS Reimbursement Lags Cardiac Device Approvals: Should Value Endpoints be Added to Trials?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content